Vanguard Group Inc Atossa Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 6,598,296 shares of ATOS stock, worth $8.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,598,296

Previous 6,485,877 1.73%

Holding current value

$8.05 Million

Previous $7.72 Million 29.94%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.09 - $1.52 $122,536 - $170,876	112,419 Added 1.73%	6,598,296 $10 Million
Q2 2024 Aug 13, 2024	BUY	$1.03 - $2.1 $753,840 - $1.54 Million	731,884 Added 12.72%	6,485,877 $7.72 Million
Q1 2024 May 10, 2024	BUY	$0.8 - $1.89 $62,615 - $147,928	78,269 Added 1.38%	5,753,993 $10.4 Million
Q2 2023 Aug 14, 2023	SELL	$0.6 - $1.28 $13,087 - $27,919	-21,812 Reduced 0.38%	5,675,724 $7.15 Million
Q4 2022 Feb 10, 2023	BUY	$0.5 - $1.01 $1,394 - $2,816	2,789 Added 0.05%	5,697,536 $3.02 Million
Q3 2022 Nov 14, 2022	SELL	$0.82 - $1.14 $572,786 - $796,312	-698,520 Reduced 10.93%	5,694,747 $4.75 Million
Q2 2022 Aug 12, 2022	SELL	$0.85 - $1.28 $424,276 - $638,910	-499,149 Reduced 7.24%	6,393,267 $6.97 Million
Q1 2022 May 13, 2022	SELL	$1.11 - $1.74 $87,061 - $136,475	-78,434 Reduced 1.13%	6,892,416 $8.62 Million
Q4 2021 Feb 14, 2022	SELL	$1.6 - $3.27 $136,977 - $279,947	-85,611 Reduced 1.21%	6,970,850 $11.2 Million
Q3 2021 Nov 12, 2021	BUY	$2.89 - $6.4 $3.74 Million - $8.28 Million	1,293,835 Added 22.45%	7,056,461 $23 Million
Q2 2021 Aug 13, 2021	BUY	$1.52 - $8.62 $8.76 Million - $49.7 Million	5,762,626 New	5,762,626 $36.4 Million

Others Institutions Holding ATOS

# of Institutions

Shares Held

26.5M

Call Options Held

466K

Put Options Held

91.8K

View Full List

About ATOSSA THERAPEUTICS, INC.

Ticker ATOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,624,000
Market Cap $154M
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...

More about ATOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Atossa Therapeutics, Inc. Transaction History